On August 10, 2018 the US Food and Drug Administration (FDA) approved ONPATTRO™, a nanomedicine for treating the devastating and usually lethal hereditary illness known as hereditary transthyretin-induced amyloidosis (hATTR).… Read More »“A new era of medicine:” NMIN thought leaders in Nature Nanotechnology

On August 21, 2019, the Board of Directors approved NMIN’s initial investments of $4.3M in nanomedicines research. Over a two-year period, NMIN will support 20 innovative projects led by Canadian… Read More »NMIN releases first round of Research Investment

Over 100 delegates—researchers, trainees, partner organization representatives and other stakeholders—gathered at the Sheraton Vancouver Wall Centre in Vancouver, British Columbia, on September 13-14, 2019, to take part in NMIN’s first… Read More »NMIN holds its first Scientific Meeting

UBC attracts over $40M to host Networks of Centres of Excellence in nanomedicines Apr 16, 2019 – The NanoMedicines Innovation Network (NMIN) has been awarded $18.5 million in new funding… Read More »NMIN receives funding from NCE Program